CBCT Brands: Ownership, Support, and Corporate Reality (2026)

Chapter 1 of 10 · What Your CBCT Dealer Won't Tell You · 2026 National Edition

Before we discuss what to buy — let's discuss who you're buying from. Not every brand name tells the full story of the company behind it today. Some do. Some don't. This chapter gives you the framework to tell the difference — before image quality, software features, or financing promotions enter the conversation.

In dental imaging, brand recognition and corporate reality have diverged in ways that have significant consequences for warranty support, parts availability, product development, and your long-term ownership experience. Most buyers begin with a machine they've seen before — at a trade show, in a CE course, in an existing supplier's catalog, or in a marketing brochure. That's normal. That's by design — manufacturers spend significant marketing budgets to make sure of it. What matters is knowing how to look past it. Before you commit to any one brand, understand the deeper corporate reality behind the logo — because that reality is what will support your practice, or fail it, over the next decade.

The examples in this chapter are drawn from publicly available sources and are presented to illustrate ownership, corporate structure, and market dynamics — not to endorse or criticize any manufacturer.

Why This Matters

A warranty is only as good as the company obligated to honor it. A support line is only as good as the team staffing it. Parts availability is only as good as the supply chain maintaining it. When a brand changes ownership — through acquisition, merger, or private equity investment — each of these can change dramatically. The name on the machine stays the same. The company behind it may not.

Patterns Worth Recognizing

Multiple Ownership Transfers

A brand that has passed through multiple ownership changes can carry compounding risk. Each transfer shifts support obligations and potentially disrupts parts supply chains and institutional knowledge. The warranty technically transfers. The practical ability to honor it depends entirely on the current entity.

One publicly documented example: the platform currently sold as the DEXIS OP3D traces through a chain of corporate owners — KaVo under Danaher Corporation, then Danaher's 2019 spin-off of its dental segment into Envista Holdings, then Envista's 2022 rebranding of the entire KaVo imaging business as DEXIS — a matter of public record confirmed by company press releases and SEC filings [1]. The core OP3D platform was first introduced globally in 2017, with updated configurations launching as late as 2019 [2]. It ran essentially unchanged under two brand names for six years before new models appeared. The entry-level unit remains in the lineup today, continuing to sell on the heritage of a brand name built by companies that no longer own it. This isn't necessarily disqualifying — it's context. The question worth asking about any established brand: what has actually changed in the product, and who is accountable for what was promised?

A live footnote to that history: as of this writing, the same platform can still be found offered through some sales channels under the original KaVo branding — at times in aggressively priced packages bundled with a portable X-ray unit. There is nothing improper about a company selling through its remaining branded inventory. But recognize the offer for what it is: a 2017-era platform wearing a heritage name, sweetened with bundle math (Chapter 3 covers why "free goods" deserve their own scrutiny). Evaluate it as exactly that — and price it as exactly that.

Private Equity Acquisition

When a dental imaging brand moves into private equity ownership, the accountability structure changes fundamentally. Public companies have disclosure obligations. PE-owned companies answer to their investors — not to the market, and not to their customers. The risk isn't that the machine stops working tomorrow. It's that the priorities determining what gets funded — R&D, support staffing, parts inventory — shift quietly in a direction that doesn't favor your long-term ownership experience.

Two documented examples: Carestream Dental has operated under private equity ownership since its 2017 carve-out to Clayton, Dubilier & Rice and Hillhouse/CareCapital [3]. In September 2024 it announced a recapitalization raising more than $525 million in new capital — a transaction the company said would significantly reduce debt and extend maturities, with new investors taking equity stakes and CD&R continuing as a minority owner [4]. Continued investment is a positive signal; a debt restructuring is also a reminder to understand exactly who backs the warranty today, and in what financial condition. Osstem Implant, parent of Hiossen, was taken private by a private equity consortium and delisted from Korea's Kosdaq exchange in August 2023 [5, 6]. In all such cases, it is advisable to scrutinize the written terms of product support in the long term.

Understand what typically happens after a take-private, too. When a consortium pays a premium to acquire a manufacturer, the investment case usually depends on cost rationalization — and the levers available are exactly the ones that affect you as an owner: R&D budgets, support staffing, parts inventory, and where the next generation of product is engineered and built. That is not a prediction about any one company. It is the standard playbook of the ownership model, and it is why the questions below deserve straight answers, in writing, before you sign.

Before committing to any PE-owned brand, take these four steps: search the brand name alongside its parent company name — ownership structures are disclosed in press releases and business registries. Ask your dealer in writing who specifically backs the warranty — the brand, the parent entity, or the dealer. And request a multi-year manufacturer-backed labor warranty from the US subsidiary. Finally, ask where the next generation of this product line will be engineered and manufactured — and whether current-unit parts and support commitments survive any change in sourcing. If those commitments aren't available in writing, you have your answer about where service ranks in their priorities.

Brand Identity Transfer — When the Reputation and the Reality Diverge

A third pattern worth recognizing is brand identity transfer — where the specific reputation that drove purchasing decisions belongs to a previous owner, not the current one. PreXion built its US market following on the strength of Japanese precision manufacturing, operating under Japan's Funai Electric group. In September 2025, the business was transferred to Alliage, a Latin American dental technology group, as announced in the acquiring company's press release [7]. The Japanese engineering identity that buyers were specifically choosing is now under different ownership — and PreXion's own materials now describe manufacturing taking place in Brazil. The brand name is the same. The corporate reality behind it is not. This is not a judgment on Alliage's intentions. It is a reminder that when you buy a brand, you are buying the current company — not its history. Ask what the current owner specifically commits to: manufacturing location, R&D investment, parts supply chain, and US support infrastructure. Get those commitments in writing. PreXion is the most recent documented example of this pattern in the US dental CBCT market — but it is not the only one. Brand names in this industry frequently outlast the companies that built them.

Financial Distress at the Parent Level

Parent company financial health directly affects product line investment and support capacity. Dentsply Sirona — parent of the Orthophos CBCT line — announced a restructuring plan in February 2023 reducing its global workforce by approximately 8–10% [8], followed by a second announced reduction of 2–4% in July 2024, disclosed alongside quarterly results in which net sales declined year-over-year [9]. Both rounds were publicly disclosed. The signals worth watching at any publicly traded parent company aren't hard to find — they're in SEC filings, press releases, and earnings reports. Workforce reductions, leadership turnover, net sales declines, goodwill impairments, and product portfolio reviews are all public disclosures. A company managing those conditions simultaneously is making prioritization decisions. The question is where a legacy CBCT product line falls in those priorities.

Distribution Politics and Brand Reputation — Know the Difference

Some brands carry reputations — positive or negative — shaped more by commercial relationships than product quality. When manufacturers concentrate distribution through a single channel partner, brand reputation becomes dependent on that partner's relationships. When partnerships fracture, brands get caught in the crossfire. When manufacturers compete directly against their own dealers, dealers stop investing in the brand. The product may not have changed. The story around it has. Genoray and Megagen are among the brands whose market reputations have been shaped as much by distribution history as by the products themselves.

Two field patterns show how this plays out. The first: single-reseller dependence. One imaging manufacturer spent years with the bulk of its US volume flowing through one dominant reseller — a structure in which other authorized dealers were left, by their own accounts, feeling like an afterthought on pricing, territory, and support. The same brand was for a time the endorsed CBCT of a major implant company; when that endorsement moved to a different manufacturer, reps who had happily sold the brand for years began steering buyers away from it almost overnight — same machines, new commissions. None of which says anything about the units themselves, which in this case are of genuinely solid quality. The company has since turned over its management team and has been visibly rebuilding its dealer and customer support. Judge the current product and the current support structure — not the residue of old commercial politics.

The second: partnership-built product lines. One implant company spent years selling another manufacturer's CBCTs as its endorsed 3D platform — at one point packaging a co-branded model with third-party planning software. The software support failed the product, the model was eventually discontinued, and — worse for the practices that had bought it — when the partnership strained, the question of who actually serviced the installed base became genuinely contested. Owners were caught in the middle of an implant company, an equipment manufacturer, and a software vendor, each pointing at the other. The partnership has since been restructured, with new models and an additional manufacturing partner — but the lesson outlives any specific arrangement: when the 3D system you're buying is really a three-way partnership, your support is only as durable as the weakest of those relationships. Ask, in writing, who contractually services the unit in year five if the partnership ends.

Before writing off a brand based on what you've heard — consider who's talking. A rep who used to distribute that brand and now sells a competitor has a financial interest in your skepticism. Don't let commercial politics make your purchasing decision. Evaluate the product on its current merits, ask the questions in this guide, and let the answers speak for themselves.

What Stable Ownership Looks Like

Not every brand in this market has a complicated ownership story. Planmeca, one of the largest privately owned dental equipment manufacturers in the world, has remained founder-led and independently owned since 1971, with manufacturing and R&D rooted in Finland [10]. Vatech is independently listed and vertically integrated, with public company materials describing it as a leading dental imaging manufacturer with offices in more than 70 countries [11]. These are the exceptions worth knowing — not because they're above scrutiny, but because they illustrate what long-term ownership stability actually looks like, and what's worth asking for from everyone else.

Read this section carefully for what it claims — and what it doesn't. Stable ownership tells you the company will likely still be there to honor its commitments. It is not a verdict on every model in the catalog. Established manufacturers are also disciplined businesses, and a time-tested way to convert brand trust into margin is the entry-level model: a unit whose headline FOV is achieved through stitched acquisition (Chapter 3), sold year after year, padded with a "free goods" bundle the manufacturer itself produces. The logo earns the company a hearing. The specific model still has to pass the Chapter 3 framework on its own.

The Due Diligence Checklist

• Who owns this brand today — and has ownership changed in the last 3–5 years?
• Where is the unit currently manufactured?
• Is R&D active on this product line, or is it a maintained legacy platform?
• Who specifically backs the warranty — the brand, the parent company, or a US distributor?
• Are replacement parts — including X-ray tube and sensor — stocked and available in the United States?
• Is there active US-based support infrastructure — or is support consolidated or outsourced?

None of these factors automatically disqualify a manufacturer. The point is not to avoid a particular company. The point is to understand who you are trusting to support a six-figure piece of equipment over the next decade. Ask the questions. Verify the answers. Then evaluate the machine itself.